Rapid changes in key Alzheimer's protein described in humans

August 29, 2008

For the first time, researchers have described hour-by-hour changes in the amount of amyloid beta, a protein that is believed to play a key role in Alzheimer's disease, in the human brain. A collaborative team of scientists at Washington University School of Medicine in St. Louis and the University of Milan report their results this week in Science.

"Proving that we can directly measure amyloid beta in the human brain is an important step forward for both clinical and basic research, and that may be true not just in Alzheimer's disease but also in other serious neurological disorders," says co-first author David L. Brody, M.D., Ph.D., a Washington University neurologist who treats brain injury and general neurology patients at Barnes-Jewish Hospital.

The results of the study contradicted the expectations of researchers, who were hoping to learn why brain injury is linked to higher risk of Alzheimer's disease. They had hypothesized that such injuries, caused by motor vehicle accidents, assaults and falls, would lead to an increase in amyloid beta levels. Instead, they found recovery from brain injury, rather than the injury itself, seemed to increase amyloid. The better a patient's overall neurological status, the higher their amyloid beta levels rose.

"We can't at this point rule out a very early spike in amyloid right after a brain injury," notes Brody, assistant professor of neurology. "This study is just the beginning."

Amyloid beta levels were measured using a technique called microdialysis, which involves placing a small catheter into the brain tissue to sample the fluid in the spaces between cells. The Italian group, headed by Sandra Magnoni, M.D., and Nino Stocchetti, M.D., and located at the Ospedale Maggiore Policlinico, a major trauma center in Milan, brought substantial previous experience with microdialysis to the study.

In the study, 18 patients recovering from traumatic brain injuries or ruptured brain aneurysms had microdialysis catheters placed in their brain tissues to measure amyloid beta while they were in the intensive care unit. Patients' families in both St. Louis and Milan gave permission in advance, and the catheters were placed when the patients were having other monitoring procedures performed.

"The results have potentially important clinical implications because the measurement of amyloid beta in the human brain may turn out to be a good indicator of how well brain cells are communicating with each other, even in very sick patients," says senior author David M. Holtzman, M.D., the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology at Washington University. "If the results are validated in further studies, this may assist physicians in making important patient management decisions in patients with acute neurological disorders."

In a study published in 2005, Holtzman and others showed that brain cell communication was directly linked to the levels of amyloid beta in a mouse model of Alzheimer's disease. When there was increased communication between brain cells, amyloid beta increased. When there was reduced communication, amyloid beta decreased. However, it was not known whether the same relationship between brain cell communication and amyloid beta levels would hold in humans.

"The new data fit well with the previous results in mice, because improved neurological status is likely to go along with increased communication between brain cells," says Brody. He and his colleagues plan to continue with similar studies that also will include direct measurement of brain electrical activity and the assessment of different forms of amyloid beta.

The results provide scientists important clues about the general origins of Alzheimer's. Further investigation is needed to answer the specialized question of why brain injury increases risk of Alzheimer's. This experiment was a test of a model that suggests brain injury accelerates harmful processes that cause Alzheimer's. Although scientists didn't find what they expected, this model still cannot be ruled out, according to Brody.

"We haven't measured how brain injury affects amyloid beta inside cells, nor have we determined whether brain injury affects the ability of amyloid beta to form small aggregates that may be especially harmful," he explains.

A second explanation for the link between brain injury and Alzheimer's suggests that injury may reduce the brain's ability to compensate for Alzheimer's-related damage, making the symptoms of the disease evident much earlier than they would otherwise appear. Evidence exists for both models, and both could be valid in different settings, according to Brody.

Brody emphasizes the researchers' gratitude to the families of patients who agreed to participate in the study. While the study did not directly benefit the patients, it provided scientists with an important opportunity to learn about amyloid beta and the connections between Alzheimer's and brain injury.

"Our ultimate goal is to develop interventions that we can apply after a traumatic brain injury to improve outcomes and reduce the long-term risk of Alzheimer's," he says.

Washington University School of Medicine in St. Louis

Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism (RSC Drug Discovery)
by Ana Martinez (Editor), David E Thurston (Editor)

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how...

Amyloid-beta: Webster's Timeline History, 1988 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Amyloid-beta," including when used in literature (e.g. all authors that might have Amyloid-beta in their name). As such, this book represents the largest compilation of timeline events associated with Amyloid-beta when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

Amyloid Beta: Webster's Timeline History, 1987 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Amyloid Beta," including when used in literature (e.g. all authors that might have Amyloid Beta in their name). As such, this book represents the largest compilation of timeline events associated with Amyloid Beta when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

Alzheimer's Disease: Cellular and Molecular Aspects of Amyloid beta (Subcellular Biochemistry)
by Robin Harris (Editor), Falk Fahrenholz (Editor)

This book contains a survey of present-day research into the biomedical fundamentals of Alzheimer’s disease (AD). It contains 20 chapters dealing with widely ranging topics, all of which have a bearing upon the understanding and treatment of AD. Starting with a broad survey of the contribution that the various microscopical techniques (light microscopy, electron microscopy, atomic force microscopy) have made since the seminal light microscopical studies of Alois Alzheimer, the book presents chapters on specialist topics: transgenic mouse models of AD; the enzymology of amyloid-ß production and degradation; oxidant stress and antioxidant protection; the involvement of metal ions and the influence of chelators; the importance of amyloid-ß oligomers and fibrils, the role of cholesterol...

Amyloid Proteins
by Jean D. Sipe (Editor)

A first-stop reference on proteins associated with amyloidosis.
This book is the first to present a systematic overview of all known fibril-forming proteins, including their biochemical characteristics and pathophysiology. It considers the clinically recognized amyloid proteins that are known to be associated with the amyloid protein folding disorders, dealing with their common structural and thermodynamic features that lead to amyloid fibril formation and disease. Emphasis is on the thermodynamics of protein folding, the structure and physiologic effects of common oligomeric and subfibrillar intermediates and the influence of the extracellular matrix and cellular trafficking and metabolism on the genesis and catabolism of beta pleated sheet proteins.
The chapters on specific...

Amyloid, Prions, and Other Protein Aggregates, Part B, Volume 412 (Methods in Enzymology)
by Ronald Wetzel (Editor), Indu Kheterpal (Editor)

The ability of polypeptides to form alternatively folded, polymeric structures such as amyloids and related aggregates is being increasingly recognized as a major new frontier in protein research. This new volume of Methods in Enzymology along with Part C (volume 413) on Amyloid, Prions and other Protein Aggregates continue in the tradition of the first volume (309) in containing detailed protocols and methodological insights, provided by leaders in the field, into the latest methods for investigating the structures, mechanisms of formation, and biological activities of this important class of protein assemblies.

* Presents detailed protocols
* Includes troubleshooting tips
* Provides coverage on structural biology, computational...

Amyloid, Prions, and Other Protein Aggregates, Part C, Volume 413 (Methods in Enzymology)
by Ronald Wetzel (Editor), Indu Kheterpal (Editor)

The ability of polypeptides to form alternatively folded, polymeric structures such as amyloids and related aggregates is being increasingly recognized as a major new frontier in protein research. This new volume of Methods in Enzymology along with Part B (volume 412) on Amyloid, Prions and other Protein Aggregates continue in the tradition of the first volume (309) in containing detailed protocols and methodological insights, provided by leaders in the field, into the latest methods for investigating the structures, mechanisms of formation, and biological activities of this important class of protein assemblies.

* Presents detailed protocols
* Includes troubleshooting tips
* Provides coverage on structural biology, computational...

Amyloid Precursor Protein: A Practical Approach
by Weiming Xia (Editor), Huaxi Xu (Editor)

In the search for an effective treatment for Alzheimer's disease, APP is a unique model protein that illustrates the wide array of basic and sophisticated characterization techniques available.

Exploring a variety of biological techniques to clarify the structure and function of this transmembrane protein, this text presents each method with detailed, step-by-step protocols to achieve reproducible results and provide a framework for studying other membrane proteins.

The Structure and Function of Alzheimer's Amyloid Beta Proteins (Medical Intelligence Unit)
by David Schubert (Editor)

Fibrous Proteins: Amyloids, Prions and Beta Proteins, Volume 73 (Advances in Protein Chemistry)
by John M. Squire (Author), David A.D. Parry (Author), Andrey Kajava (Author)

Amyloids, Prions and Beta Proteins is the last volume of the three-part thematic series on Fibrous Proteins in the Advances in Protein Chemistry serial. Fibrous proteins act as molecular scaffolds in cells providing the supporting structures of our skeletons, bones, tendons, cartilage, and skin. They define the mechanical properties of our internal hollow organs such as the intestines, heart, and blood vessels. This volume covers such topics as Beta-Structures in Fibrous Proteins; B-Silks: Enhancing and Controlling Aggregation; Beta-Rolls, Beta-Helices and Other Beta-Solenoid Proteins; Natural Triple B-Stranded Fibrous Folds; Structure, Function and Amyloidogenesis of Fungal Prions: Filament Polymorphism and Prion Variants; X-Ray Fiber and powder Diffraction of PRP Prion Peptides; From...